Articles from Vektor Medical

Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, today announced the publication of a groundbreaking case in Heart Rhythm Case Reports. Conducted by physicians from the University of California San Diego (UCSD), the case details the first successful use of AI-enabled ECG mapping to guide left bundle branch area pacing (LBBAP) implantation. Findings highlight how vMap, a non-invasive AI-powered mapping technology, enhances procedural efficiency, accuracy, and patient safety during LBBAP lead positioning.

Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, today announced key leadership appointments to support commercial expansion and market entry initiatives. Michael Andersen has joined the company as Vice President, Sales, and Mihir Naik has been promoted to Vice President, Quality Assurance and Regulatory Affairs. These key moves position Vektor for rapid growth following its recently oversubscribed $25M Series A funding round.

Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, is proud to announce key milestones achieved throughout 2024, underscoring a year defined by accelerated growth, technological innovation, and meaningful clinical impact. From the widespread adoption of vMap to groundbreaking clinical data and enhanced reimbursement pathways, Vektor Medical remains steadfast in its mission to transform arrhythmia care.

Vektor Medical, a leader in non-invasive arrhythmia analysis and localization, announced today the presentation of new data showcasing the significant capabilities of vMap, its AI-powered solution for enhancing cardiac arrhythmia treatment. To be presented on November 17 at the American Heart Association (AHA) Scientific Sessions 2024, this data highlights vMap’s impressive 91.1% accuracy rate in differentiating epicardial from endocardial ventricular tachycardia, outperforming traditional visual ECG analysis, which achieved only 62.5% accuracy.

Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, will present findings today at HRX 2024. The two studies showcase how Vektor’s advanced technologies uniquely leverage AI and deep learning to assess wall thickness and scar tissue in ventricular tachycardia (VT) patients, providing crucial insights for electrophysiologists performing ablation procedures. Both studies will be featured during the Top 5 AbstracX session at 2:45 PM, highlighting the highest-scoring abstracts submitted to HRX 2024.

Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology, today unveiled a comprehensive schedule of educational content and sessions featuring the use of vMap® at this year’s Heart Rhythm 2024 conference in Boston, May 16-19.

Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology, today announced the publication of data in the Journal of Cardiovascular Electrophysiology (JACE) demonstrating vMap’s ability to reduce the time from mapping to treatment, procedure duration, and fluoroscopy when treating cardiac arrhythmia patients with ablation therapy.

Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology, today announced a $16 million Series A investment co-led by Solas BioVentures and TVM Capital Life Science. This funding underscores investor confidence in Vektor’s vision and ability to successfully execute its mission to revolutionize arrhythmia care.

Vektor Medical, a pioneer in non-invasive arrhythmia analysis technology, will release findings today at AF Symposium from the recent study Ablation of Non-Pulmonary Vein Atrial Fibrillation Drivers Identified by Machine Learning in Addition to Pulmonary Vein Isolation Improves Procedural Outcomes. Additionally, Dr. Jag Singh, a world-renowned expert in artificial intelligence, medical sensors, and the future of healthcare, will present on vMap as part of the Symposium’s Spotlight Sessions.

Vektor Medical, a pioneer in non-invasive arrhythmia analysis technology, is proud to highlight two studies showcasing vMap®’s novel application in the analysis and treatment of ventricular arrhythmias. Both studies are being presented by Dr. Gordon Ho, Associate Professor of Medicine at UC San Diego Health.

Vektor Medical, a pioneer in arrhythmia care and developer of vMap®, the world’s first technology to accurately map arrhythmias using the patient’s 12-lead ECG data, announces the American Medical Association (AMA) CPT Editorial Panel has approved a new Category III CPT code for the use of vMap’s noninvasive arrhythmia analysis.

Vektor Medical, a pioneer in arrhythmia care and developer of the only FDA-cleared non-invasive technology to accurately map arrhythmias using just 12-lead ECG data, is delighted to announce the expansion of its esteemed Medical Advisory Board.

Vektor Medical, developers of the only FDA-cleared technology to accurately map arrhythmias using just 12-lead ECG data, is set to showcase two innovative research breakthroughs at HRX 2023, the Heart Rhythm Society’s digital health innovation conference. The company’s Chief Technology Officer, Chris Villongco, Ph.D., and Vice President of Technology, Christian Márton, Ph.D., were selected as AbstracX Innovators and will unveil groundbreaking research on CT Scar Imaging and Wall Thickness Analysis, illuminating the broad potential of non-invasive arrhythmia analysis and Vektor Medical’s vMap technology.

Vektor Medical, developer of the only technology to accurately map arrhythmias using just 12-lead ECG data, today announced the release of a series of software enhancements to its AI-based non-invasive solution, vMap. Designed to improve ablation outcomes and procedural efficiencies, the newly updated vMap software integrates additional automation and advanced visualization features.

Vektor Medical, pioneers of the world’s first technology to accurately map arrhythmias using only 12-lead ECG data, today unveiled two studies further demonstrating clinical utility. The first study showcases vMap’s utility in unstable ventricular tachycardia (VT) ablation, sometimes called ‘unmappable VT’. The second study, a proof-of-concept effort, demonstrated a brand-new opportunity to map Atrial Tachycardia using 12-lead ECG data obtained in the outpatient setting. Results will be presented at the Heart Rhythm Society’s Annual Conference 2023 in New Orleans.

Vektor Medical, developer of the vMap® next-generation arrhythmia mapping technology, today announced former Philips and Biotronik medical technology leader Marlou Janssen and Yale Clinical Professor of Medicine and past American College of Cardiology (ACC) Connecticut Chapter Governor and President Dr. Craig McPherson have joined Vektor’s advisory board.

Vektor Medical, developer of the world’s only technology to rapidly map arrhythmias using just 12-lead ECG data, today announced that use of the vMap® arrhythmia mapping system during complex atrial fibrillation (AF) ablation was associated with significantly improved freedom from atrial arrhythmias compared with standard-of-care pulmonary vein isolation. The results will be presented at the Biomarkers and Personalized Medicine in Cardiovascular Disease Symposium on Saturday, March 25, in La Jolla, California.

Vektor Medical, developer of vMap® — the world’s first FDA-cleared technology to localize arrhythmias from just 12-lead ECG data — will present complex case studies that expand vMap’s utility at the Annual American College of Cardiology (ACC) Scientific Session held March 4-6, 2023 in New Orleans.

Vektor Medical, developer of the world’s first technology to rapidly map cardiac arrhythmias using only 12-lead ECG data, today announced it presented new data on its vMap® technology that demonstrated potential utility in patients with adult congenital heart disease (ACHD) and refractory atrial fibrillation (AF) at the recent 15th Annual Asia Pacific Heart Rhythm Society (APHRS) Scientific Session.

Vektor Medical, the developer of the world’s first technology to rapidly map cardiac arrhythmias using only 12-lead ECG data, announced study results that demonstrate a significant reduction in total procedural duration, fluoroscopy use, and cost after implementation of vMap®. The research was presented by Avinash Toomu, UC San Diego Health, at the American College of Physicians Southern California Chapters 1, 2, 3 Poster Competition and Scientific Program on Saturday, October 8, 2022. The poster presentation won first place in the research category.

Vektor Medical, the developer of the world’s first technology to rapidly map cardiac arrhythmias using only 12-lead ECG data, today announced Circulation: Arrhythmia and Electrophysiology has published a peer-reviewed manuscript of the clinical data from a study evaluating the accuracy of its vMap® technology. The system, which was cleared by the U.S. Food and Drug Administration in November 2021, demonstrated high accuracy for vMap in identifying arrhythmia sources throughout the heart.

Vektor Medical today announced positive results from its “Vektor vMap™ Clinical Validation Study” evaluating the accuracy of cardiac mapping with vMap™. The study achieved statistically significant results of 98.7% in accurately identifying the regional arrhythmia source location for premature ventricular complex (PVC) and ventricular tachycardia (VT), 96.9% in accurately identifying the regional arrhythmia source for the arrhythmias and pacing types studied, and 97.3% segment mapping accuracy in all nine arrhythmia and pacing types included.